TrialOncotarget2016

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.

Francesco Perrone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.